Evidence map›Paper›PMID 40874559›Full record

ReviewNanomedicine (London, England)2025

Strategies to enhance the effects of nanotechnology-mediated photodynamic therapy.

Yanhan Mo, Xu Liu, Jian You, Lihua Luo

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yanhan MoCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Xu LiuThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P. R. China.
Jian YouCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Lihua LuoCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.

Funding

National Natural Science Foundation of China
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a noninvasive therapeutic approach, particularly effective in tumor treatment. PDT utilizes photosensitizers (PSs) to absorb light at specific wavelengths, converting photon energy into chemical energy and subsequently generating cytotoxic reactive oxygen species (ROS). These ROS trigger cell death through apoptosis, necrosis and autophagy-related pathways. Compared with conventional therapies, PDT exhibits significant advantages, including high selectivity, repeatability, enhanced safety, minimal side effects, low drug resistance, and compatibility with radiotherapy or chemotherapy. However, due to the limited tissue penetration depth of light, PDT demonstrates suboptimal efficacy in treating deep tumors. Additionally, limitations such as poor targeting of photosensitizers and unfavorable factors in the tumor microenvironment greatly restrict PDT's therapeutic efficacy and clinical applicability. To enhance PDT efficacy, various strategies have been explored, among which nanotechnology has emerged as a key research focus. This review summarizes multiple approaches to augmenting nanotechnology-mediated PDT, with emphasis on achieving targeted delivery of photosensitizers (tissue, cell, and organelle-level), improving the performance of photosensitizers and modulating the tumor microenvironment. These insights provide theoretical guidance and practical references for developing novel and efficient PDT nanoplatforms. We conducted the literature search in PubMed, Elsevier ScienceDirect, Web of Science, Wiley and Scopus (from 2004 to 2025).

Indexed as

NanotechnologyNeoplasmsPhotochemotherapyPhotosensitizing AgentsAnimalsDrug Delivery SystemsHumansNanomedicineNanoparticlesReactive Oxygen SpeciesTumor MicroenvironmentPhotosensitizing AgentsReactive Oxygen SpeciesnanotechnologyPhotodynamic therapyphotosensitizertargettumor microenvironment

Identifiers

PMID40874559
PMCPMC12490413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.